Alzheimer’s Therapeutics Market Key Highlights:
- Market Size (2024): USD 4.90 Billion
- Projected Market Size (2034): USD 8.60 Billion
- CAGR (2023-2034): 5.8%
Pricing Analysis:
- Price Growth
- Regional Variations
Market Historic Sales
- Total sales volume, year-over-year growth, product categories, and market share.
Revenue Estimation
- Forecasting future revenues based on historical data, market trends, and economic indicators.
Sales by Region
- Breakdown of sales performance across different geographical areas.
Revenue by Manufacturer
- Analysis of revenue contributions from different manufacturers in the market.
Alzheimer’s Therapeutics Market Definition
The Alzheimer's therapeutics market deals in the manufacturing and distribution of medicines used in the treatment of Alzheimer's disease worldwide. Various drug classes are used for treating Alzheimer's, such as cholinesterase inhibitors, NMDA Receptor antagonists, combination drugs, and others. These medicines are available on several platforms, including offline pharmacies and e-commerce platforms.
The rising incidences of Alzheimer’s disease among people across the world have increased the demand for Alzheimer's therapeutics, thereby driving market growth. Also, the growing application of these therapeutics in disease progression and symptom management has led to the expansion of the industry. Moreover, the increasing emphasis on improving brain health, along with several developments in neuroscience research, is positively shaping the industry in a positive direction. Furthermore, the rise in the number of hospitals associated with treating Alzheimer's, coupled with increased demand for cholinesterase inhibitors and rivastigmine, is projected to foster the growth of the Alzheimer's therapeutics market.
The development of amyloid-fighting medications and the rise in the number of clinical trials associated with these therapeutics are expected to create ample growth opportunities for the market players in the upcoming days. In July 2024, the U.S. Food and Drug Administration announced the approval of Kisunla. Kisunla is an injection that is found effective for the treatment of Alzheimer’s disease.
Alzheimer’s Therapeutics Market Segmentation:
By Type
- Donepezil
- Memantine
- Rivastigmine
By Application
- Early to Moderate Stages
- Moderate to Severe Stages
Alzheimer’s Therapeutics Market Companies:
- Pfizer
- Merck &
- Novartis AG
- Eisai
- H. Lundbeck A/S
- AC Immune
- TauRx Pharmaceuticals
- Actavis plc.
- Forest Laboratories
- Teva Pharmaceuticals Industries
- Janssen Pharmaceutical
- GE healthcare
- Eli Lilly And Company
- DiaGenic ASA
- VTV Therapeutics
- Hoffman-La Roche
- AstraZeneca
- Daiichi Sankyo Company
For any questions about this dataset or to discuss customization options, please write to us at sales@statifacts.com
